|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Mirati_Therapeutics,_Inc.
|
|
gptkbp:activities
|
inhibits KRAS mutations
|
|
gptkbp:approves
|
gptkb:United_States
|
|
gptkbp:clinical_trial
|
gptkb:Mirati_Therapeutics
Phase 2
ongoing studies
specific criteria
Phase 1, Phase 2, Phase 3
positive outcomes
multiple sites
progression-free survival
analyzed for efficacy
|
|
gptkbp:collaborations
|
academic institutions
biotech companies
|
|
gptkbp:competitors
|
other KRAS inhibitors
|
|
gptkbp:developed_by
|
gptkb:Mirati_Therapeutics
|
|
gptkbp:dosage_form
|
once daily
|
|
gptkbp:duration
|
varies by patient
|
|
gptkbp:educational_programs
|
provided by Mirati Therapeutics
|
|
gptkbp:feedback
|
collected for improvement
|
|
gptkbp:future_plans
|
planned for new indications
|
|
gptkbp:grants
|
awarded for further studies
|
|
gptkbp:healthcare
|
associated with treatment
necessary for prescribing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mirati's KRAS inhibitor
|
|
gptkbp:indication
|
gptkb:healthcare_organization
|
|
gptkbp:interacts_with
|
with other medications
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
required during treatment
|
|
gptkbp:is_tested_for
|
KRAS G12 C
|
|
gptkbp:is_used_for
|
treatment of cancer
|
|
gptkbp:launch_date
|
gptkb:2021
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
Krazati
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibition of downstream signaling pathways
|
|
gptkbp:population
|
advanced solid tumors
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
included in oncology protocols
|
|
gptkbp:publishes
|
peer-reviewed journals
|
|
gptkbp:receives_funding_from
|
gptkb:Company
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
required for approval
|
|
gptkbp:research
|
demonstrated efficacy
|
|
gptkbp:research_areas
|
targeted therapy
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:safety_features
|
monitored in trials
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
monitoring required
|
|
gptkbp:student_enrollment
|
ongoing in trials
|
|
gptkbp:supply_chain
|
managed by Mirati Therapeutics
|
|
gptkbp:target_audience
|
patients with KRAS G12 C mutation
|
|
gptkbp:targets
|
gptkb:KRAS_gene
|
|
gptkbp:treatment
|
monitored long-term
with other cancer drugs
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:year_created
|
gptkb:2020
|